Malignant Thoracic Neoplasm

MCF-7 cells were transduced with YFP tagged EGFR with D770_N771INSSVD mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased… (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC

In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. T… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V834I mutation, and was treated with the 1st generation TKI gefitinib. The pati… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V851I mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

Using NGS, genomic profiling from tumor/plasma biopsies from 17,442 Chinese lung cancer patients was performed. EGFR::VSTM2A reported in 2/1053 recurrent kinase fusions in lung cancer (NSCLC, adenocar… (full text at CIViC)

PMID 34508169 · Li et al., 2021 · Open in CIViC

Deguelin inhibits EGFR signaling in wild-type NSCLC cells. It reduces EGFR phosphorylation and downstream signalling, as shown by decreased phosphorylation of Akt and ERK1/2. This effect was not obser… (full text at CIViC)

PMID 32081857 · Gao et al., 2020 · Open in CIViC

In a phase 3 clinical trial of East Asian pulmonary adenocarcinoma patients, a subset of patients with EGFR mutations (n=261) treated with gefitinib were associated with improved response compared to … (full text at CIViC)

PMID 19692680 · Mok et al., 2009 · Open in CIViC

While EGFR mutation is a strong predictive factor for EGFR inhibition, some patients with EGFR wild-type also respond. The authors investigated whether phosphorylated EGFR could be a potential predic… (full text at CIViC)

PMID 22901364 · Wang et al., 2012 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR Y764_V765insHH demonstrated reduced sensitivity to erlotinib treatment (IC50=3.845�M), comparable to Ba/F3 cells expressing EGFR L858R and T790M… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

A 66 year old male with 10 pack year smoking history and lung adenocarcinoma with EGFR Y764_V765insHH mutation was given gefitinib as first line treatment, and had stable disease as best response with… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

An EGFR::YAP1 fusion was reported in a patient with non-small cell lung cancer. The breakpoint in EGFR is given as exon 26. Breakpoint in YAP1 is not specified.

PMID 31064887 · Guan et al., 2019 · Open in CIViC

This is a case report of a patient with lung adenocarcinoma harboring EGFR::RAD51 fusion, however describes other EGFR fusions in lung adenocarcinoma. The authors examined data from the database of Or… (full text at CIViC)

PMID 31064887 · Guan et al., 2019 · Open in CIViC

In the PROFILE 1001 study, from 31 NSCLC tumors positive for ALK fusions with sufficient material for RT-PCR aided exon breakpoint identification, 1 case of EML4-ALK variant 2 (EML4 exon 20 fused to A… (full text at CIViC)

PMID 20979469 · Kwak et al., 2010 · Open in CIViC

EML4-ALK variants v1 (E13;A20), v2 (E20;A20), v3a (E6;A20) and v3b (E6ins33;A20) were expressed in Ba/F3 cells using retrovirus. While all constructs rendered Ba/F3 cells IL3-independant, marked diff… (full text at CIViC)

PMID 22912387 · Heuckmann et al., 2012 · Open in CIViC

Multiplex RT-PCR to detect in-frame fusions of EML4 to ALK was performed on total RNA from 253 lung adenocarcinomas, and 9 samples were found to contain such fusions, one of which was a novel fusion c… (full text at CIViC)

PMID 18927303 · Takeuchi et al., 2008 · Open in CIViC

In a cohort of 75 NSCLC patients that had tested positive for 3 EML4-ALK rearrangements, two individuals were identified via RT-PCR with a novel EML4-ALK translocation involving the first 6 exons of E… (full text at CIViC)

PMID 18593892 · Choi et al., 2008 · Open in CIViC

In a panel of 602 cancer cell lines, 3/134 NSCLC cell lines showed <0.5% cell viability following treatment with the ALK inhibitor TAE684. Of these, NCI-H2228 harbored EML4-ALK variant 3a/b (EML4 exon… (full text at CIViC)

PMID 18451166 · McDermott et al., 2008 · Open in CIViC

A 33 year old M non-smoker with no cancer family history and no known exposure to asbestos showed weakness, chest pain, and plural effusion (PE) accumulation. Mass in right lung was seen under enhance… (full text at CIViC)

PMID 32600123 · Hu et al., 2020 · Open in CIViC

A 28 year-old patient with non-small cell lung cancer that failed conventional therapy was found to harbor the EML4-ALK (E13;A20) fusion using reverse transcription PCR. Treatment with 250mg crizotini… (full text at CIViC)

PMID 20979473 · Choi et al., 2010 · Open in CIViC

EML4-ALK fusion positive lung adenocarcinoma cell lines with high expression of P-gp (ABCB1 gene) (H3122 and the newly established JFCR013-2) were found to be resistant to crizotinib and ceritinib. P-… (full text at CIViC)

PMID 26870817 · Katayama et al., 2016 · Open in CIViC

EML4-ALK fusion positive lung adenocarcinoma cell lines (H3122 and the newly established JFCR013-2) with high expression of P-gp (ABCB1 gene) were found to be resistant to crizotinib and ceritinib. P… (full text at CIViC)

PMID 26870817 · Katayama et al., 2016 · Open in CIViC

This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One out of 11 patients with acquired crizot… (full text at CIViC)

PMID 22235099 · Doebele et al., 2012 · Open in CIViC

One patient with ALK-rearranged non-small cell lung cancer and an acquired resistance to crizotinib showed new ALK amplification (4.1 fold increase compared to pre-crizotinib specimen as measured by F… (full text at CIViC)

PMID 23344087 · Kim et al., 2013 · Open in CIViC

A 28 year-old patient with T4N3M1 stage lung adenocarcinoma harboring an EML4-ALK variant 1 fusion was treated with crizotinib after failing conventional therapy. The patient achieved a partial respon… (full text at CIViC)

PMID 20979473 · Choi et al., 2010 · Open in CIViC

In a non-small cell lung cancer patient with a liver metastatic tumor harboring an ALK gene rearrangement and an ALK C1156Y co-mutation, ALK C1156Y was reported to be refractory to 7-month crizotinib … (full text at CIViC)

PMID 23434628 · Huang et al., 2013 · Open in CIViC

Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.

PMID 21030459 · Sasaki et al., 2010 · Open in CIViC

A 52 year old male never smoker was diagnosed with stage IV NSCLC adenocarcinoma and was treated with chemotherapy with eventual disease progression. He tested positive for ALK rearrangement via break… (full text at CIViC)

PMID 26775591 · Kodityal et al., 2016 · Open in CIViC

A 52 year old with a non-smoking history was diagnosed with stage IV NSCLC-adenocarcinoma and treated with chemotherapy. Upon disease progression, the initial diagnostic biopsy tested positive for AL… (full text at CIViC)

PMID 26775591 · Kodityal et al., 2016 · Open in CIViC

In an analysis of 83 ALK positive NSCLC patients treated with multiple ALK inhibitors, one patient biopsy showed G1202del mutation after progressing on ceritinib. In addition, Ba/F3 cell lines express… (full text at CIViC)

PMID 27432227 · Gainor et al., 2016 · Open in CIViC